限局性前立腺癌の治療 : 内分泌療法

Abstract

限局性前立腺癌症例47例中, 内分泌療法を中心とした治療を行った28例の治療成績について, 同時期に前立腺全摘除術を施行した19例と比較した. 1)全生存率では前立腺全摘除術施行症例で高い傾向にあったが, cause specific survivalならびにdisease free survivalでは両治療群の間に差は認められなかった. 2)内分泌療法群では, 組織学的分化度がdisease free survivalに影響を及ぼし, 低分化型腺癌では有意に高い再発が認められた. 3)限局性前立腺癌症例の内分泌療法は, 高齢者或いはリスクの高い合併症を有する症例等に対して選択されるべき一治療法である

We assessed the actuarial survival of 28 patients with localized prostate cancer who were treated with endocrine therapy in comparison with that of 19 patients who had radical prostatectomy between 1972 and 1995. There were no significant differences among the cause-specific curves and clinical disease-free survival of patients treated with endocrine therapy and radical prostatectomy but the all-cause survival curves favored the surgery group. The results of endocrine therapy alone were unsatisfactory for the patients with high grade tumors. In conclusion, the patients with localized prostate cancer at high risk of death from other complications are reasonable candidates for endocrine therapy.